Company Description
Neurometrix (NASDAQ: NURO) is a publicly traded medical devices company in the Surgical & Medical Instruments & Apparatus sector. The company has a market capitalization of $8.9M, ranking #6,476 among all listed U.S. companies by market cap.
NURO stock has gained 3.1% over the past year. Shares last traded at $4.58.
This page provides a comprehensive overview of NURO stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Neurometrix (NURO) stock last traded at $4.58. Over the past 12 months, the stock has gained 3.1%. At a market capitalization of $8.9M, NURO is classified as a micro-cap stock with approximately 2.1M shares outstanding.
Latest News
Neurometrix has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include acquisition, earnings, conferences. View all NURO news →
SEC Filings
Neurometrix has filed 1 recent SEC filing, including 1 Form SCHEDULE 13G/A. The most recent filing was submitted on August 13, 2025. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all NURO SEC filings →
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Neurometrix (NURO) currently stands at 161 shares, down 92.9% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 92.9%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Neurometrix (NURO) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
NURO Company Profile & Sector Positioning
Neurometrix (NURO) operates in the Medical Devices industry within the broader Surgical & Medical Instruments & Apparatus sector and is listed on the NASDAQ.